InMode Ltd. Ordinary Shares - INMD STOCK NEWS

DOMA Perpetual Capital Management, a major InMode (NYSE: INMD) shareholder, has sent a letter to the company's Board urging immediate action to enhance shareholder value. The letter criticizes InMode's current stock price of around $16 and highlights the company's substantial cash position of approximately $640 million with no debt.

DOMA demands a 30% tender offer in Q1 2025, followed by a 10% share buyback later in 2025. The investor estimates InMode will generate about $150 million in free cash flow in 2025. The letter also criticizes recent management decisions, including the firing of key executives and lack of production diversification outside Israel.

DOMA proposes several actions including reducing cash levels to below $100 million, establishing a small dividend program, and implementing strategic capital allocation. The investor has retained legal counsel and threatens further action if the Board fails to respond appropriately.

InMode (Nasdaq: INMD) announced it will release its Q4 and full year 2024 financial results on February 6, 2025, before the Nasdaq market opens. The company is finalizing its results, which are expected to reflect significant challenges in the aesthetics industry due to broader macroeconomic conditions.

Preliminary results indicate:

• Q4 revenue is expected between $97.0 million and $97.5 million.
• Full-year 2024 revenue is projected between $394.0 million and $394.5 million.
• Non-GAAP gross margin for the full year 2024 is expected to range from 80% to 81%.
• 2025 revenue is forecasted to be between $395 million and $405 million.

A conference call to discuss the results will be held on February 6, 2025, at 8:30 a.m. Eastern Time, featuring presentations from CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. Participants are encouraged to pre-register for the call to receive a unique dial-in for immediate access. The call will also be webcast live on InMode's website, with a replay available until February 13, 2025, and for 90 days on the company's website.

InMode (INMD), a leading global provider of innovative medical technologies, has announced its participation in four major investor conferences during November and December 2024. The company will be represented at the UBS Global Healthcare Conference in California, the Jefferies London Healthcare Conference in the UK, the Canaccord Genuity MedTech Forum in New York, and the Mizuho Medical Device Summit in New York.

CFO Yair Malca and CEO Moshe Mizrahy will participate in fireside chats and one-on-one meetings. Live webcasts will be available for the UBS and Jefferies conferences, scheduled for November 12 and November 20, respectively.

InMode (INMD) reported Q3 2024 GAAP revenue of $130.2 million, including $98.3 million in net sales and $31.9 million from H1 2024 pre-orders, marking a 5.8% increase from Q3 2023. Consumables and service revenue decreased 11% to $15.8 million. The company reported GAAP net income of $51.0 million ($0.65 per share) and non-GAAP net income of $55.0 million ($0.70 per share). Due to macroeconomic challenges, InMode revised its full-year 2024 revenue guidance down to $410-420 million from $430-440 million. Gross margins declined to 82% from 84% in Q3 2023.

InMode (INMD) has secured a preliminary injunction from the U.S. District Court for the Central District of California against sellers of counterfeit Morpheus8 radiofrequency devices and accessories. The court order, issued by Judge Michael Fitzgerald on September 3, 2024, includes asset freezing and listing removals for involved sellers. The company previously obtained a Temporary Restraining Order due to public safety concerns regarding counterfeit medical products. CEO Moshe Mizrahy emphasized the company's zero-tolerance approach to counterfeit products and commitment to public safety. InMode will continue enforcement actions against counterfeit sellers and directs U.S. patients to verify authorized providers through their website.

InMode (Nasdaq: INMD) anticipates releasing its Q3 2024 financial results on October 30, 2024. Preliminary expectations include:

- Q3 revenue between $130.0-$130.1 million, including $31.9 million from H1 2024 pre-orders
- Non-GAAP gross margin of 81-82%
- Revised full-year 2024 revenue guidance to $410-$420 million, down from $430-$440 million

The company fulfilled all pre-orders for two new platforms introduced earlier this year. However, macro-economic factors continue to impact the aesthetics industry. InMode is prioritizing employee safety amid the current situation in Israel and considering relocating some production activities.

A conference call to discuss Q3 results is scheduled for October 30, 2024, at 8:30 a.m. Eastern Time.

InMode (Nasdaq: INMD) announced the departure of three key executives from its North American operations as part of a global reorganization strategy. Shakil Lakhani, President of North America, Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA, have left the company. InMode has also changed management teams in three European subsidiaries.

This restructuring aligns with InMode's global expansion and penetration into new business verticals, particularly the wellness sector. The role of President of North America will be divided to better manage the company's growth and full pipeline of new platforms. CEO Moshe Mizrahy emphasized that this new structure aims to enhance operational efficiency in North America and build a robust infrastructure for future growth.

InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced a new share repurchase program of up to 7.68 million ordinary shares. This decision follows the completion of a previous buyback program earlier this year, reflecting the company's ongoing confidence in its long-term outlook.

CEO Moshe Mizrahy emphasized the board's confidence in the company's future, while CFO Yair Malca highlighted InMode's continued profitability and cash generation, even in challenging economic conditions. The company believes there will be no tax implications from the existing program. The repurchases will be funded with available cash and may be commenced, suspended, or discontinued at any time.

InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in the 2024 Baird Global Healthcare Conference in New York on September 10, 2024. Key points include:

• CFO Yair Malca will present in-person at a fireside chat moderated by Jeff Johnson, Senior Research Analyst
• The presentation is scheduled for 2:00 pm Eastern Time
• A live webcast of the presentation will be available
• InMode will hold one-on-one investor meetings on the same day

This event provides an opportunity for investors to gain insights into InMode's operations and future prospects. Interested parties can access more information about the event on InMode's investor relations site.